var data={"title":"Valacyclovir: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Valacyclovir: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7134?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=valacyclovir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Valacyclovir: Patient drug information&quot;</a> and <a href=\"topic.htm?path=valacyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Valacyclovir: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232799\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Valtrex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50788690\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Valtrex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232819\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent;</li>\n      <li>\n        Antiviral Agent, Oral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232803\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes labialis (cold sores):</b> Oral: 2 g every 12 hours for 1 day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes labialis (cold sores) in HIV-infected patients (off-label use):</b> Oral: 1 g twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes zoster (shingles):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunocompetent patients: 1 g 3 times daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-infected patients, acute localized dermatomal (off-label use): 1 g 3 times daily for 7 to 10 days; consider longer duration if lesions resolve slowly (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes simplex virus (HSV), genital infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial episode:</i> Immunocompetent patients: 1 g twice daily for 10 days.  <b>Note:</b> CDC STD guidelines recommend a treatment duration of 7 to 10 days (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Recurrent episode:</i> Immunocompetent patients: 500 mg twice daily for 3 days or alternatively (off-label dose), 1,000 mg once daily for 5 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Reduction of transmission:</i> 500 mg once daily (source partner)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Suppressive therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompetent patients: 1 g once daily (500 mg once daily in patients with &le;9 recurrences per year). <b>Note:</b> Safety and efficacy have been documented for up to 1 year (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-infected patients (CD4 &ge;100 cells/mm<sup>3</sup>): 500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: HIV-infected patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial or recurrent episodes (off-label use):</i> 1 g twice daily for 5 to 10 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic suppressive therapy: </i>500 mg twice daily; continue indefinitely regardless of CD4 count in patients with severe recurrences or in patients who want to minimize frequency of recurrences (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>B virus, postexposure prophylaxis (off-label use): </b>Oral: 1 g 3 times daily for 14 days (Tunkel 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CMV reactivation (prevention in allogeneic HSCT recipients) (off-label use):</b> Oral: 2 g 3 to 4 times daily; in combination with screening for CMV reactivation; begin at engraftment and continue to day 100 (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV keratitis (off-label use) </b>\n      <b>(White 2014): Oral</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epithelial keratitis, dendritic:</i> 500 mg twice daily for 7 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epithelial keratitis, geographic:</i> 1 g 3 times daily for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Stromal keratitis, without epithelial ulceration:</i> 500 mg once daily; use in combination with therapeutic dose of topical corticosteroid, for the duration of corticosteroid treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Stromal keratitis, with epithelial ulceration:</i> 1 g 3 times daily for 7 to 10 days, then reduce to 500 mg once daily; use in combination with therapeutic dose of topical corticosteroid, for the duration of corticosteroid treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endothelial keratitis:</i> 500 mg twice daily for 7 to 10 days, then reduce to 500 mg once daily; use in combination with therapeutic dose of topical corticosteroid, for the duration of corticosteroid treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HSV reactivation (prevention in seropositive HSCT recipients) (off-label use) (Tomblyn 2009):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Early reactivation:</i> 500 mg once daily <b>or</b> 500 mg twice daily in highly immune-suppressed patients (eg, T cell depletion, anti-T cell antibodies, high-dose steroids). Initiate at the beginning of conditioning therapy and continue until engraftment or until mucositis resolves</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Late reactivation:</i> 500 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella (chickenpox) in HIV-infected patients (off-label use):</b> 1 g 3 times daily for 5 to 7 days in uncomplicated cases (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella zoster virus (VZV) acute retinal necrosis (ARN) in HIV-infected patients (off-label use): </b>Oral: 1 g 3 times daily for 6 weeks following initial treatment with acyclovir IV and intravitreal ganciclovir (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VZV, postexposure prophylaxis (HSCT recipients) (off-label use):</b> Oral: 1 g 3 times daily; initiate within 96 hours (preferably, 48 hours) of exposure and continue until 22 days after exposure (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>VZV reactivation (prevention in HSCT recipients) (off-label use): </b>Oral: 500 mg twice daily for 1 year after HSCT (Tomblyn 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232813\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=valacyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Valacyclovir: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes labialis (cold sores):</b> Children &ge;12 years and Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes labialis (cold sores) in HIV-infected patients (off-label use):</b> Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes simplex virus, genital infection in HIV-infected patients: </b>Adolescents (off-label population): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial or recurrent episodes (off-label use):</i> 1 g twice daily for 5 to 14 days (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chronic suppressive therapy (off-label dose):</i> 500 mg twice daily; continue indefinitely regardless of CD4 count in patients with severe recurrences or in patients who want to minimize frequency of recurrences (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Herpes zoster (shingles) in HIV-infected patients (off-label use):</b> Adolescents: Oral: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Varicella (chickenpox):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immunocompetent patients:</i> Children &ge;2 years and Adolescents: Oral: 20 mg/kg/dose 3 times daily for 5 days (maximum: 1 g 3 times daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV-infected patients (off-label use):</i> Adolescents: Oral: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232804\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232805\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Herpes zoster:</i></b>  Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 49 mL/minute: 1 g every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 29 mL/minute: 1 g every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Genital herpes:</i></b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial episode:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: 1 g every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recurrent episode: CrCl &lt;29 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suppressive therapy: CrCl &lt;29 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For usual dose of 1 g every 24 hours or 500 mg every 12 hours, decrease dose to 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For usual dose of 500 mg every 24 hours, decrease dose to 500 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial episode:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: 1 g every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Recurrent episode:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Suppressive therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 29 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immunocompetent or HIV-infected patients: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immunocompetent patients with &le;9 recurrences/year: 500 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immunocompetent or HIV-infected patients: 500 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Immunocompetent patients with &le;9 recurrences/year: 500 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Herpes labialis <i>(cold sores)</i>:</i></b> Adolescents and Adults <i>(US labeling) </i>or Adults <i>(Canadian labeling)</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 49 mL/minute: 1 g every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 29 mL/minute: 500 mg every 12 hours for 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: 500 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Dialyzable (~33% removed during 4-hour session); administer dose postdialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chronic ambulatory peritoneal dialysis/continuous arteriovenous hemofiltration dialysis: Pharmacokinetic parameters are similar to those in patients with ESRD; supplemental dose not needed following dialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5702788\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232774\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valtrex: 500 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valtrex: 1 g [scored; contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg, 1 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232759\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232778\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">If GI upset occurs, administer with meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232777\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of herpes zoster (shingles) in immunocompetent patients; treatment of first-episode and recurrent genital herpes in immunocompetent patients; suppression of recurrent genital herpes and reduction of transmission of genital herpes in immunocompetent patients; suppression of genital herpes in HIV-infected individuals; treatment of herpes labialis (cold sores); chickenpox in immunocompetent children</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744941\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>B virus, postexposure prophylaxis; CMV reactivation (prevention in allogeneic HSCT recipients); Herpes simplex virus (HSV), genital infection in HIV-infected patients (adolescents and adults); HSV keratitis; HSV, orolabial (cold sores) infection in HIV-infected patients (adolescents and adults); HSV reactivation (prevention in seropositive HSCT recipients); Herpes zoster (shingles) in HIV-infected patients (adolescents and adults); Varicella infection (chickenpox) in HIV-infected patients (adolescents and adults); Varicella zoster virus (VZV) acute retinal necrosis (ARN) in HIV-infected patients (adolescent and adults); VZV, postexposure prophylaxis (HSCT recipients); VZV reactivation (prevention in HSCT recipients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232826\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Valtrex may be confused with Keflex, Valcyte, Zovirax</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ValACYclovir may be confused with acyclovir, valGANciclovir, vancomycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232766\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (13% to 38%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (5% to 15%), abdominal pain (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (2% to 16%), increased serum ALT (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (&le;16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (&le;8%), depression (&le;7%), dizziness (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (&le;6%), diarrhea (children: 5%; adults: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysmenorrhea (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (&le;3%), leukopenia (&le;1%; mild)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinorrhea (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, agitation, alopecia, anemia, aplastic anemia, ataxia, brain disease, coma, confusion, delirium, dysarthria, erythema multiforme, facial edema, hallucination (auditory and visual), hemolytic-uremic syndrome, hepatitis, hypersensitivity reaction (acute; includes anaphylaxis, angioedema, dyspnea, pruritus, skin rash, urticaria), hypertension, hypersensitivity angiitis, increased serum creatinine, loss of consciousness, mania, psychosis, renal failure, renal pain, seizure, skin photosensitivity, tachycardia, thrombotic thrombocytopenic purpura, tremor, urinary urgency, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232781\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to valacyclovir, acyclovir, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232763\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: CNS adverse effects (including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy) have been reported in both adult and pediatric patients with or without renal dysfunction. Elderly patients are more likely to experience CNS adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic microangiopathy: Has occurred in immunocompromised patients (at doses of 8 g/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment, the elderly, and/or those receiving nephrotoxic agents. Acute renal failure and CNS effects have been observed in patients with renal dysfunction; dose adjustment may be required. Precipitation in renal tubules may occur; maintain adequate hydration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; CNS effects have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunocompromised patients: Advanced HIV (CD4 &lt;100 cells/mm<sup>3</sup>): Safety and efficacy have not been established for treatment/suppression of recurrent genital herpes or disseminated herpes in patients with profound immunosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For cold sores, treatment should begin with earliest symptom (tingling, itching, burning). For genital herpes, treatment should begin as soon as possible after the first signs and symptoms (within 72 hours of onset of first diagnosis or within 24 hours of onset of recurrent episodes). For herpes zoster, treatment should begin within 72 hours of onset of rash. For chickenpox, treatment should begin with earliest sign or symptom.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300201\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP1A2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232768\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10034&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Acyclovir-Valacyclovir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate. Mycophenolate may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Acyclovir-Valacyclovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible.  If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Varicella Virus Vaccine.  Management: When possible, avoid use of acyclovir or valacyclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of these antiviral agents for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zoster Vaccine (Live/Attenuated): Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine (Live/Attenuated).  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232770\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232784\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Valacyclovir is metabolized to acyclovir. In a pharmacokinetic study, maternal acyclovir serum concentrations were higher in pregnant women receiving valacyclovir than those given acyclovir for the suppression of recurrent herpes simplex virus (HSV) infection late in pregnancy. Amniotic fluid concentrations were also higher; however, there was no evidence that fetal exposure differed between the groups (Kimberlin 1998). Data from an acyclovir pregnancy registry has shown no increased rate of birth defects than that of the general population; however, the registry is small and the manufacturer notes that use during pregnancy is only warranted if the potential benefit to the mother justifies the risk of the fetus. Because more data is available for acyclovir, that agent is preferred for the treatment of genital herpes in pregnant women (CDC [Workowski 2015]); however, valacyclovir may be considered for use due to its simplified dosing schedule (HHS [OI adult 2015]). Pregnant women who have a history of genital herpes recurrence, suppressive therapy is recommended starting at 36-weeks gestation (HHS [OI adult 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232785\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Valacyclovir is rapidly metabolized to acyclovir. Following administration of valacyclovir, acyclovir is present in breast milk; unchanged valacyclovir has not been detected in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following administration of valacyclovir, the relative infant dose (RID) of acyclovir is 5.1% when calculated using the highest average breast milk concentration located and compared to an infant therapeutic dose of intravenous acyclovir of 30 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest average milk concentration (10.15 mcg/mL), the estimated daily infant acyclovir dose via breast milk is 1.52 mg/kg/day. This milk concentration was obtained following maternal administration of valacyclovir 500 mg twice daily (Drake 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Peak acyclovir milk concentrations occurred 4 hours (range: 2 to 4 hours) following maternal administration of a single oral dose of valacyclovir 500 mg; the half-life of acyclovir in breast milk was ~2 hours (range: 1.3 to 12.2 hours) (Sheffield 2002). Acyclovir was able to be detected in the urine of breastfeeding infants following 5 days of treatment with valacyclovir 500 mg twice daily (Sheffield 2002).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommends that caution be used if administered to a breastfeeding woman. Other sources note that women with HSV infection taking valacyclovir may breastfeed as long as there are not lesions on the breast, body lesions are covered, and strict hand hygiene is practiced (ACOG 2007; Jaiyeoba 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232772\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinalysis, BUN, serum creatinine, liver enzymes, and CBC</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232762\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Valacyclovir is rapidly and nearly completely converted to acyclovir by intestinal and hepatic metabolism. Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232780\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Acyclovir is widely distributed throughout the body including brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, and CSF </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~14% to 18%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; valacyclovir is rapidly and nearly completely converted to acyclovir and L-valine by first-pass effect; acyclovir is hepatically metabolized to a very small extent by aldehyde oxidase and by alcohol and aldehyde dehydrogenase (inactive metabolites) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~55% once converted to acyclovir </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: Children: 1.3 to 2.5 hours, slower clearance with increased age; Adults: Acyclovir: 2.5-3.3 hours, Valacyclovir: ~30 minutes; End-stage renal disease: Acyclovir: 14 to 20 hours; During hemodialysis: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Children: 1.4 to 2.6 hours; Adults: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine, primarily as acyclovir (89%); <b>Note:</b> Following oral administration of radiolabeled valacyclovir, 46% of the label is eliminated in the feces (corresponding to nonabsorbed drug), while 47% of the radiolabel is eliminated in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232783\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (ValACYclovir HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (30): $379.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (30): $216.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Valtrex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (30): $751.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (90): $1,288.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232787\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alaclov (BD);</li>\n      <li>Herclov (ID);</li>\n      <li>Iclofar (ID);</li>\n      <li>Inclovir (ID);</li>\n      <li>Ovalac (BD);</li>\n      <li>Rapivir (CR, DO, GT, HN, MX, NI, PA, SV, UY);</li>\n      <li>Revira (BD);</li>\n      <li>Rivacir (HU);</li>\n      <li>Shilova (AU);</li>\n      <li>Talavir (IT);</li>\n      <li>Vaciclor (SG);</li>\n      <li>Vaclovir (AU);</li>\n      <li>Vacyless (TW);</li>\n      <li>Vadiral (CO);</li>\n      <li>Valaclor (KR);</li>\n      <li>Valarux (BD);</li>\n      <li>Valasil (KR);</li>\n      <li>Valcivir (IN);</li>\n      <li>Valcyclor (CO);</li>\n      <li>Valextra (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Valotix (IE);</li>\n      <li>Valovir (ET, SG, ZW);</li>\n      <li>Valraci (KR);</li>\n      <li>Valtcro (KR);</li>\n      <li>Valtra (HK, KR);</li>\n      <li>Valtrex (AE, AR, AT, AU, BB, BD, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CY, CZ, DE, EC, EE, EG, ES, FI, GB, GR, GY, HK, ID, IE, IL, IQ, IR, IS, JM, JO, JP, KR, KW, LB, LT, LV, LY, MT, MY, NO, NZ, OM, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SR, SY, TH, TR, TT, TW, VE, YE);</li>\n      <li>Valvir (AU, ID, LK, SG);</li>\n      <li>Viranet (AR);</li>\n      <li>Zelitrex (AU, BE, DK, FR, NL, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. No. 82 June 2007. Management of herpes in pregnancy. <i>Obstet Gynecol</i>. 2007 109(6):1489-1498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/17569194/pubmed\" target=\"_blank\" id=\"17569194\">17569194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acosta EP and Fletcher CV, &ldquo;Valacyclovir,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(2):185-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9034421/pubmed\" target=\"_blank\" id=\"9034421\">9034421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alrabiah FA and Sacks SL, &ldquo;New Antiherpesvirus Agents. Their Targets and Therapeutic Potential,&rdquo; <i>Drugs</i>, 1996, 52(1):17-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/8799682/pubmed\" target=\"_blank\" id=\"8799682\">8799682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. <i>Cutis.</i> 2003;71(3):239-242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/12661753/pubmed\" target=\"_blank\" id=\"12661753\">12661753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beutner KR, Friedman DJ, Forszpaniak C, et al, &ldquo;Valacyclovir Compared With Acyclovir for Improved Therapy for Herpes Zoster in Immunocompetent Adults,&rdquo; <i>Antimicrob Agents Chemother</i>, 1995, 39(7):1546-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/7492102/pubmed\" target=\"_blank\" id=\"7492102\">7492102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bodsworth NJ, Crooks RJ, Borelli S, et al, &ldquo;Valaciclovir Versus Aciclovir in Patients Initiated Treatment of Recurrent Genital Herpes: A Randomized, Double-Blind Clinical Trial. International Valaciclovir HSV Study Group,&rdquo; <i>Genitourin Med</i>, 1997, 73(2):110-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9215092/pubmed\" target=\"_blank\" id=\"9215092\">9215092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Drake AL, Roxby AC, Kiarie J, et al. Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial. <i>PLoS One</i>. 2012;7(4):e34635.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/22509337/pubmed\" target=\"_blank\" id=\"22509337\">22509337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grant DM, Mauskopf JA, Bell L, et al, &ldquo;Comparison of Valaciclovir and Acyclovir for the Treatment of Herpes Zoster in Immunocompetent Patients Over 50 Years of Age: A Cost-Consequence Model,&rdquo; <i>Pharmacotherapy</i>, 1997, 17(2):333-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9085325/pubmed\" target=\"_blank\" id=\"9085325\">9085325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated July 14, 2016. Accessed January 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hyland PL, Coulter WA, Abu-Ruman I, et al. Asymptomatic shedding of HSV-1 in patients undergoing oral surgical procedures and attending for noninvasive treatment. <i>Oral Dis.</i> 2007;13(4):414-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/17577329/pubmed\" target=\"_blank\" id=\"17577329\">17577329</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaiyeoba O, Amaya MI, Soper DE, et al, &quot;Preventing Neonatal Transmission of Herpes Simplex Virus,&quot; <i>Clin Obstet Gynecol</i>, 2012, 55(2):510-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/22510634/pubmed\" target=\"_blank\" id=\"22510634\">22510634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DF, Weller S, Whitley RJ, et al, &quot;Pharmacokinetics of Oral Valacyclovir and Acyclovir in Late Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 1998, 179(4):846-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9790357/pubmed\" target=\"_blank\" id=\"9790357\">9790357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel R, Bodsworth NJ, Woolley P, et al, &ldquo;Valaciclovir for the Suppression of Recurrent Genital HSV Infection: A Placebo Controlled Study of Once Daily Therapy. International Valaciclovir HSV Study Group,&rdquo; <i>Genitourin Med</i>, 1997, 73(2):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9215091/pubmed\" target=\"_blank\" id=\"9215091\">9215091</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry CM and Faulds D, &ldquo;Valaciclovir. A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Herpesvirus Infections,&rdquo; <i>Drugs</i>, 1996, 52(5):754-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9118821/pubmed\" target=\"_blank\" id=\"9118821\">9118821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada, &ldquo;Canadian Guidelines on Sexually Transmitted Infections.&quot; Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php. Accessed August 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rahimi H, Mara T, Costella J, Speechley M, Bohay R. Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systemic review and meta-analysis. <i>Oral Surg Oral Med Oral Pathol Oral Radiol.</i> 2012;113:618-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/22668620/pubmed\" target=\"_blank\" id=\"22668620\">22668620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reitano M, Tyring S, Lang W, et al, &ldquo;Valaciclovir for the Suppression of Recurrent Genital Herpes Simplex Virus Infection: A Large-Scale Dose Range-Finding Study. International Valaciclovir HSV Study Group,&rdquo; <i>J Infect Dis</i>, 1998, 178(3):603-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9728526/pubmed\" target=\"_blank\" id=\"9728526\">9728526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10847274\"></a>Rivaud E, Massiani MA, Vincent F, Azoulay E, Coudrec LJ. Valacyclovir hydrochloride therapy and thrombotic thrombocytopenic purpura in an HIV-infected patient. <i>Arch Intern Med</i>. 2000;160(11):1705-1706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/10847274/pubmed\" target=\"_blank\" id=\"10847274\">10847274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sheffield JS, Fish DN, Hollier LM, Cadematori S, Nobles BJ, Wendel GD Jr. Acyclovir concentrations in human breast milk after valaciclovir administration. <i>Am J Obstet Gynecol</i>. 2002;186(1):100-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/11810093/pubmed\" target=\"_blank\" id=\"11810093\">11810093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;47(3):303-327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/18582201/pubmed\" target=\"_blank\" id=\"18582201\">18582201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tyring SK, Douglas JM Jr, Corey L, et al, &ldquo;A Randomized, Placebo-Controlled Comparison of Oval Valacyclovir and Acyclovir in Immunocompetent Patients With Recurrent Genital Herpes Infections. The Valaciclovir International Study Group,&rdquo; <i>Arch Dermatol</i>, 1998, 134(2):185-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/9487210/pubmed\" target=\"_blank\" id=\"9487210\">9487210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated September 24, 2015. Accessed September 25, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Valacyclovir,&rdquo; <i>Med Lett Drugs Ther</i>, 1996, 38(965):3-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/8551979/pubmed\" target=\"_blank\" id=\"8551979\">8551979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valtrex (valacyclovir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weller S, Blum MR, Doucette M, et al, &ldquo;Pharmacokinetics of the Acyclovir Prodrug Valaciclovir After Escalating Single- and Multiple-Dose Administration to Normal Volunteers,&rdquo; <i>Clin Pharmacol Ther</i>, 1993, 54(6):595-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/8275615/pubmed\" target=\"_blank\" id=\"8275615\">8275615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White ML, Chodosh J. Herpes Simplex Virus Keratitis: A Treatment Guideline. Available at: https://www.aao.org/clinical-statement/herpes-simplex-virus-keratitis-treatment-guideline. Accessed January 24, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/valacyclovir-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10034 Version 218.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232799\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50788690\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F232819\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F232803\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F232813\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F232804\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F232805\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5702788\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232774\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F232759\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F232778\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F232777\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744941\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F232826\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232766\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232781\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232763\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300201\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F232768\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232770\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F232784\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F232785\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F232772\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232762\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F232780\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F232783\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F232787\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10034|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=valacyclovir-patient-drug-information\" class=\"drug drug_patient\">Valacyclovir: Patient drug information</a></li><li><a href=\"topic.htm?path=valacyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Valacyclovir: Pediatric drug information</a></li></ul></div></div>","javascript":null}